Editorial Comment to the March 2014 Issue of IMARS Highlights

Editorial comments

This issue publishes the articles of three active Maillard researchers. The first article is a mini review written by Prof. Kiyotaka Nakagawa at Tohoku University, Japan, entitled “Biological roles of Amadori-glycated phosphatidylethanolamine: involvement of lipid glycation in the development of diabetic complications”. Recent evidence emphasizes the involvement of lipid glycation and lipid oxidation in diabetic complications. Prof. Nakagawa summarized the biological impact of the glycated lipids, especially Amadori- phosphatidylethanolamine, leading to disorders of cellular integrity, which contributes to development of diabetic complications.

The second article is a mini review written by Profs. Sung Min Son and Inhee Mook-Jung at Seoul National University, Korea, entitled “The interaction of Advanced Glycation Endproducts (AGEs) with the receptor (RAGE): Implication for Alzheimer’s disease”. They updated the understanding about the effect of AGEs and RAGE in pathogenesis of Alzheimer’s disease. Further, they focused on the benefits of the blockade of AGEs-RAGE axis as a promising therapeutic target.

The third article entitled “Development of simple assay method for screening of AGE inhibiters and the effect of the candidates on AGEs formation” is a memorial review written byDr. Yukio Fujiwara, a winner of Young Investigator Award of the 23nd Japanese Maillard Reaction Society (JMARS) meeting held on November 29 in Osaka last year. In this article, he summarized the establishment of ELISA system, which is able to measure amount of several specific AGEs structure (CML, CMA and Pentosidine) and the usefulness of the ELISA system to indentify novel AGE inhibitors.

The IMARS Highlights editors look forward to your contribution to the field of food and medical glycation researches as always. Please contact us.

Reiko Inagi, PhD

Division of Chronic Kidney Disease Pathophysiology,
The University of Tokyo Graduate School of Medicine

email: [email protected]

Comment are closed.